Galectin Therapeutics (NASDAQ:GALT) Director Harold Shlevin Sells 16,790 Shares

Galectin Therapeutics Inc. (NASDAQ:GALT) Director Harold Shlevin sold 16,790 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $6.27, for a total value of $105,273.30. Following the transaction, the director directly owned 11,206 shares in the company, valued at $70,261.62. This represents a 59.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Galectin Therapeutics Price Performance

Galectin Therapeutics stock opened at $5.36 on Thursday. Galectin Therapeutics Inc. has a one year low of $0.73 and a one year high of $6.66. The business has a fifty day moving average price of $5.37 and a 200-day moving average price of $3.96. The firm has a market capitalization of $345.49 million, a P/E ratio of -9.29 and a beta of 0.95.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Sell-side analysts expect that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on GALT. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Galectin Therapeutics in a report on Thursday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $6.00.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Galectin Therapeutics by 2.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,247,967 shares of the company’s stock valued at $9,520,000 after buying an additional 63,419 shares during the period. Osaic Holdings Inc. raised its stake in shares of Galectin Therapeutics by 3.4% during the second quarter. Osaic Holdings Inc. now owns 1,265,384 shares of the company’s stock valued at $2,670,000 after acquiring an additional 41,968 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Galectin Therapeutics during the second quarter valued at about $1,580,000. Wealthspire Advisors LLC boosted its holdings in shares of Galectin Therapeutics by 20.4% during the second quarter. Wealthspire Advisors LLC now owns 479,518 shares of the company’s stock worth $1,012,000 after purchasing an additional 81,144 shares during the period. Finally, Geneos Wealth Management Inc. grew its stake in shares of Galectin Therapeutics by 8.8% in the first quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company’s stock worth $516,000 after purchasing an additional 34,300 shares during the last quarter. 11.68% of the stock is owned by hedge funds and other institutional investors.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.